Tofacitinib versus methotrexate in rheumatoid arthritis: patient-reported outcomes from the randomised phase III ORAL Start trial

OBJECTIVES: To compare patient-reported outcomes (PROs) in methotrexate (MTX)-naive patients (defined as no prior treatment or ≤3 doses) receiving tofacitinib versus MTX. METHODS: In the 24-month, phase III, randomised, controlled, ORAL Start trial (NCT01039688), patients were randomised 2:2:1 to re...

Descripción completa

Detalles Bibliográficos
Autores principales: Strand, Vibeke, Lee, Eun Bong, Fleischmann, Roy, Alten, Rieke E, Koncz, Tamas, Zwillich, Samuel H, Gruben, David, Wilkinson, Bethanie, Krishnaswami, Sriram, Wallenstein, Gene
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2016
Materias:
Rheumatoid Arthritis
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5051508/
https://www.ncbi.nlm.nih.gov/pubmed/27752357
http://dx.doi.org/10.1136/rmdopen-2016-000308

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5051508/
https://www.ncbi.nlm.nih.gov/pubmed/27752357
http://dx.doi.org/10.1136/rmdopen-2016-000308

Ejemplares similares